Patient-Reported Quality of Life with ALUNBRIG® (brigatinib)
Choose ALUNBRIG first-line for patients with ALK+ mNSCLC.1
ALUNBRIG Delayed Time to Worsening in Global Health Status (GHS)/Quality of Life (QoL) vs crizotinib2
Median Time to Worsening in GHS/QoL (≥10-Point Worsening in Score)2,a
Time to worsening was assessed by2,3:
Physical scales
Emotional, cognitive, and social functioning scales
Improvement of disease symptoms
Study Limitations: These patient-reported outcome endpoints were secondary and not prespecified. The improvement in QoL scores and delay in worsening of GHS/QoL may be an overestimation, because patients were not blinded to treatment assignment. These differences in global QoL could reflect differences in efficacy on disease-related symptoms and in treatment-related adverse events.2
Among responders, the median duration of improvement in GHS/QoL had not been reached for ALUNBRIG vs 12 months for crizotinib.2
Discover More About Quality of Life Results
aPatient-reported symptoms, functioning, and GHS/QoL were measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and supplemental QLQ-LC13 (Lung Cancer Module).2
1L, first-line; ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; CI, confidence interval; HR, hazard ratio; mNSCLC, metastatic NSCLC; NR, not reached.